Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors

Smith, Amanda M., Dun, Matthew D., Lee, Erwin M., Harrison, Celeste, Kahl, Richard, Flanagan, Hayley, Panicker, Nikita, Mashkani, Baratali, Don, Anthony S., Morris, Jonathan, Toop, Hamish, Lock, Richard B., Powell, Jason A., Thomas, Daniel, Guthridge, Mark A., Moore, Andrew, Ashman, Leonie K., Skelding, Kathryn A., Enjeti, Anoop and Verrills, Nicole M. (2016) Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget, 7 30: 47465-47478. doi:10.18632/oncotarget.10167


Author Smith, Amanda M.
Dun, Matthew D.
Lee, Erwin M.
Harrison, Celeste
Kahl, Richard
Flanagan, Hayley
Panicker, Nikita
Mashkani, Baratali
Don, Anthony S.
Morris, Jonathan
Toop, Hamish
Lock, Richard B.
Powell, Jason A.
Thomas, Daniel
Guthridge, Mark A.
Moore, Andrew
Ashman, Leonie K.
Skelding, Kathryn A.
Enjeti, Anoop
Verrills, Nicole M.
Title Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
Journal name Oncotarget   Check publisher's open access policy
ISSN 1949-2553
Publication date 2016-06-18
Sub-type Article (original research)
DOI 10.18632/oncotarget.10167
Open Access Status DOI
Volume 7
Issue 30
Start page 47465
End page 47478
Total pages 14
Place of publication Albany, NY, United States
Publisher Impact Journals LLC
Collection year 2017
Language eng
Abstract Constitutive activation of the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3), via co-expression of its ligand or by genetic mutation, is common in acute myeloid leukemia (AML). In this study we show that FLT3 activation inhibits the activity of the tumor suppressor, protein phosphatase 2A (PP2A). Using BaF3 cells transduced with wildtype or mutant FLT3, we show that FLT3-induced PP2A inhibition sensitizes cells to the pharmacological PP2A activators, FTY720 and AAL(S). FTY720 and AAL(S) induced cell death and inhibited colony formation of FLT3 activated cells. Furthermore, PP2A activators reduced the phosphorylation of ERK and AKT, downstream targets shared by both FLT3 and PP2A, in FLT3/ITD+ BaF3 and MV4-11 cell lines. PP2A activity was lower in primary human bone marrow derived AML blasts compared to normal bone marrow, with blasts from FLT3-ITD patients displaying lower PP2A activity than WT-FLT3 blasts. Reduced PP2A activity was associated with hyperphosphorylation of the PP2A catalytic subunit, and reduced expression of PP2A structural and regulatory subunits. AML patient blasts were also sensitive to cell death induced by FTY720 and AAL(S), but these compounds had minimal effect on normal CD34+ bone marrow derived monocytes. Finally, PP2A activating compounds displayed synergistic effects when used in combination with tyrosine kinase inhibitors in FLT3-ITD+ cells. A combination of Sorafenib and FTY720 was also synergistic in the presence of a protective stromal microenvironment. Thus combining a PP2A activating compound and a FLT3 inhibitor may be a novel therapeutic approach for treating AML.
Keyword AML
FLT3
FTY720
PP2A
Tyrosine kinase inhibitor
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
Admin only - CHRC
Child Health Research Centre Publications
UQ Diamantina Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 4 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 20 Nov 2016, 10:27:27 EST by System User on behalf of Learning and Research Services (UQ Library)